Harvard Bioscience Inc (NASDAQ: HBIO) flaunted slowness of -6.74% at $0.49, as the Stock market unbolted on Wednesday, before settling in for the price of $0.53 at the close. Taking a more long-term approach, HBIO posted a 52-week range of $0.28-$3.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been -18.10% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -18.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 16.67%. This publicly-traded company’s shares outstanding now amounts to $44.21 million, simultaneously with a float of $37.41 million. The organization now has a market capitalization sitting at $21.84 million. At the time of writing, stock’s 50-day Moving Average stood at $0.4089, while the 200-day Moving Average is $1.4765.
Harvard Bioscience Inc (HBIO) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Harvard Bioscience Inc industry. Harvard Bioscience Inc’s current insider ownership accounts for 15.39%, in contrast to 58.64% institutional ownership.
Harvard Bioscience Inc (HBIO) Earnings and Revenue Records
Harvard Bioscience Inc’s EPS increase for this current 12-month fiscal period is 16.67% and is forecasted to reach 0.06 in the upcoming year.
Harvard Bioscience Inc (NASDAQ: HBIO) Trading Performance Indicators
Let’s observe the current performance indicators for Harvard Bioscience Inc (HBIO). It’s Quick Ratio in the last reported quarter now stands at 0.40. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 0.24. Similarly, its price to free cash flow for trailing twelve months is now 57.47.
In the same vein, HBIO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.32, a figure that is expected to reach -0.03 in the next quarter, and analysts are predicting that it will be 0.06 at the market close of one year from today.
Technical Analysis of Harvard Bioscience Inc (HBIO)
Now, what If we examine the latest scores posted by [Harvard Bioscience Inc, HBIO]. During the last 5-days, its volume was lower the volume of 6.39 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 34.84% While, its Average True Range was 0.0786.
Raw Stochastic average of Harvard Bioscience Inc (HBIO) in the period of the previous 100 days is set at 14.01%, which indicates a major fall in contrast to 44.40% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 150.38% that was lower than 188.52% volatility it exhibited in the past 100-days period.
